This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.
The RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has ...
Authors: Patricia M. LoRusso, Jeffrey R. Infante, Kevin B. Kim, Howard A. Burris III, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson and Roger B. Cohen
Human triple-negative breast cancer has limited therapeutic choices. Breast tumor cells have depolarized plasma membrane potential. Using this unique electrical property, we aim to develop an effective selecti...
Authors: Han-Gang Yu, Sarah McLaughlin, Mackenzie Newman, Kathleen Brundage, Amanda Ammer, Karen Martin and James Coad
Neuroblastoma (NB), a tumor of the primitive neural crest, despite aggressive treatment portends a poor long-term survival for patients with advanced high stage NB. New treatment strategies are required.
Authors: Reza Bayat Mokhtari, Narges Baluch, Micky Ka Hon Tsui, Sushil Kumar, Tina S. Homayouni, Karen Aitken, Bikul Das, Sylvain Baruchel and Herman Yeger
Wogonin is an encouraging choice for clinical use owing to its potent anti-tumor and anti-inflammatory effects with the high safety profile. However, wogonin for targeted therapy of lymphoma was not well addre...
Authors: Xue Wu, Ping Liu, Haijun Zhang, Yuan Li, Jumah Masoud Mohammad Salmani, Fei Wang, Ke Yang, Rong Fu, Zhewei Chen and Baoan Chen
The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancre...
Authors: Berta Laquente, Jose Lopez-Martin, Donald Richards, Gerald Illerhaus, David Z. Chang, George Kim, Philip Stella, Dirk Richel, Cezary Szcylik, Stefano Cascinu, G. L. Frassineti, Tudor Ciuleanu, Karla Hurt, Scott Hynes, Ji Lin, Aimee Bence Lin…
Cisplatin (DDP)-based chemotherapy is the common first-line therapy for lung cancer. However, their efficacy is often limited by primary drug resistance and/or acquired drug resistance. The aim of this study w...
Authors: Lin Shi, Zhaozhong Xu, Gang Wu, Xiaoting Chen, Yuanyuan Huang, Yanjing Wang, Weiqiang Jiang and Bin Ke
Bacterial toxins have evolved to an effective therapeutic option for cancer therapy. The Clostridium perfringens enterotoxin (CPE) is a pore-forming toxin with selective cytotoxicity. The transmembrane tight junc...
Authors: Jessica Pahle, Lutz Menzel, Nicole Niesler, Dennis Kobelt, Jutta Aumann, Maria Rivera and Wolfgang Walther
Antiangiogenic therapies are considered promising for the treatment of glioblastoma (GB). The non-collagenous C-terminal globular NC1 domain of type VIII collagen a1 chain, Vastatin, is an endogenous antiangio...
Authors: Yi Li, Jun Li, Yat Ming Woo, Zan Shen, Hong Yao, Yijun Cai, Marie Chia-mi Lin and Wai Sang Poon
Photodynamic therapy (PDT) has proven to be a promising alternative to current cancer treatments, especially if combined with conventional approaches. The technique is based on the administration of a non-toxi...
Authors: Laura Marise de Freitas, Rodolfo Bortolozo Serafim, Juliana Ferreira de Sousa, Thaís Fernanda Moreira, Cláudia Tavares dos Santos, Amanda Martins Baviera, Valeria Valente, Christiane Pienna Soares and Carla Raquel Fontana
Glioblastoma Multiforme (GBM) is the most common and lethal form of primary brain tumor in adults. Following standard treatment of surgery, radiation and chemotherapy, patients are expected to survive 12–14 mo...
Authors: Zachary C. Gersey, Gregor A. Rodriguez, Eric Barbarite, Anthony Sanchez, Winston M. Walters, Kelechi C. Ohaeto, Ricardo J. Komotar and Regina M. Graham
Advanced urothelial carcinomas represent a considerable clinical challenge as they are difficult to treat. Platinum-based combination regimens obtain response rates ranging from 40 to 70% in first-line therapy...
Authors: Sergey A. Dyshlovoy, Ramin Madanchi, Jessica Hauschild, Katharina Otte, Winfried H. Alsdorf, Udo Schumacher, Vladimir I. Kalinin, Alexandra S. Silchenko, Sergey A. Avilov, Friedemann Honecker, Valentin A. Stonik, Carsten Bokemeyer and Gunhild von Amsberg
Concurrent cisplatin radiotherapy (CCRT) is a current standard-of-care for locally advanced head and neck squamous cell carcinoma (HNSCC). However, CCRT is frequently ineffective in patients with advanced dise...
Authors: Martin McLaughlin, Holly E. Barker, Aadil A. Khan, Malin Pedersen, Magnus Dillon, David C. Mansfield, Radhika Patel, Joan N. Kyula, Shreerang A. Bhide, Kate L. Newbold, Christopher M. Nutting and Kevin J. Harrington
Osteosarcoma (OS) is the most common primary bone tumor in both humans and dogs and is the second leading cause of cancer related deaths in children and young adults. Limb sparing surgery along with chemothera...
Authors: Sridhar Murahari, Aimee L. Jalkanen, Samuel K. Kulp, Ching-Shih Chen, Jaime F. Modiano, Cheryl A. London and William C. Kisseberth
Despite considerable efforts by scientific research, pancreatic cancer is the fourth leading cause of cancer related mortalities. Sigma-2 receptors, which are overexpressed in several tumors, represent promisi...
Authors: Maria Laura Pati, John R. Hornick, Mauro Niso, Francesco Berardi, Dirk Spitzer, Carmen Abate and William Hawkins
Combination drug therapy appears a promising approach to overcome drug resistance and reduce drug-related toxicities in ovarian cancer treatments. In this in vitro study, we evaluated the antitumor efficacy of...
Authors: Vijayalakshmi N. Ayyagari, Tsung-han Jeff Hsieh, Paula L. Diaz-Sylvester and Laurent Brard
Norcantharidin (NCTD) is a Chinese FDA approved, chemically synthesized drug for cancer treatment. The effect of NCTD on signaling proteins of EGFR and c-Met was systematically elucidated in current study.
Authors: Peiju Qiu, Siwen Wang, Ming Liu, He Ma, Xuan Zeng, Meng Zhang, Lingling Xu, Yidi Cui, Huixin Xu, Yang Tang, Yanli He and Lijuan Zhang
Metabolic toxicities of mTOR inhibitors (mTORi) are well characterized. The purpose of the study was to investigate the relationship between these metabolic toxicities and mTORi efficacy.
Authors: M. Jebali, R. Elaidi, M. Brizard, J. Fouque, C. Takouchop, B. Sabatier, S. Oudard and J. Medioni
In endemic area, nasopharyngeal carcinoma (NPC) tumor cells harbor EBV latent infection and expresses viral antigens such as EBNA1, LMP1 and LMP2. In this study, we established a NPC-mimicry animal model and a...
Authors: Mei-Chun Lin, Yong-Chong Lin, Syue-Ting Chen, Tai-Horng Young and Pei-Jen Lou
Colorectal cancer (CRC) is the 3rd most common type of cancer worldwide. New anti-cancer agents are needed for treating late stage colorectal cancer as most of the deaths occur due to cancer metastasis. A recentl...
Authors: Khayal Al-Khayal, Ahmed Alafeefy, Mansoor-Ali Vaali-Mohammed, Amer Mahmood, Ahmed Zubaidi, Omar Al-Obeed, Zahid Khan, Maha Abdulla and Rehan Ahmad
Colorectal cancer is the second most common cause of cancer deaths for both men and women, and the third most common cause of cancer in the U.S. Toxicity of current chemotherapeutic agents for colorectal cance...
Authors: Jeffrey Wimsatt, Meghan Villers, Laurel Thomas, Stacey Kamarec, Caitlin Montgomery, Leo W. Y. Yeung, Yanqing Hu and Kim Innes
